Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (732) 296-84

TECHNOLOGIES, INC. ANNOUNCES

BRUNSWICK, N.J. - November 16, 2009 -- Senesco Technologies, Inc. ("Senesco" or

the "Company") (NYSE Amex: SNT) today announced that, on November 16, 2009,

Bruce C. Galton resigned from his position as a member of the board of

directors. In addition, Mr. Galton resigned from his positions as the

Company's President and Chief Executive Officer to pursue other

interests. Mr. Galton and the Company currently are discussing the

terms of Mr. Galton's separation with the Company.

November 16, 2009, the Board of Directors appointed Jack Van Hulst, a current

member of the Board of Directors, to serve as the Company's President and Chief

Galton commented, "My goal has been to bring Senesco's Factor 5A technology

to the clinic to determine its utility to treat multiple myeloma, a serious bone

marrow cancer. The Company is poised to initiate its pivotal toxicology

study to support an IND application. It has been an honor and a pleasure

to bring the Company to this point."

Waksal, M.D., Senesco's Chairman, commented, "We wish Bruce well with his future

endeavors, and we look forward to having Jack as our new President and Chief

Executive Officer. I will continue to play an active role with the

Company. The Board, management and all employees remain excited about

the future of the Company."

details regarding the foregoing are disclosed on the Company's Form 8-K filed

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay

cell death in mammals (apoptosis) to determine if the technology is applicable

in human medicine. Accelerating apoptosis may have applications to development

of cancer treatments. Delaying apoptosis may have applications to certain

inflammatory and ischemic diseases. Senesco takes its name from the scientific

term for the aging of plant cells: senescence. Delaying cell breakdown in plants

extends freshness after harvesting, while increasing crop yields, plant size and

resistance to environmental stress. The Company believes that its technology can

be used to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual

results could differ materially from such statements expressed or implied herein

as a result of a variety of factors, including, but not limited to: the ability

to successfully transition to new management; the ability of the Company to

consummate additional financings; the development of the Company's gene

technology; the approval of the Company's patent applications; the successful

implementation of the Company's research and development programs and joint

ventures; the success of the Company's license agreements; the acceptance by the

market of the Company's products; success of the Company's preliminary studies

and preclinical research; competition and the timing of projects and trends in

future operating performance, as well as other factors expressed from time to

time in the Company's periodic filings with the Securities and Exchange

Commission (the "SEC"). As a result, this press release should be read in

conjunction with the Company's periodic filings with the SEC. The

forward-looking statements contained herein are made only as of the date of this

press release, and the Company undertakes no obligation to publicly update such

forward-looking statements to reflect subsequent events or